Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ: BLUE )

4.080 -2.960 (-42.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
21 22 Next >
2 Growth Stocks That Could Double in 2023
Both are lagging the market this year. 
Via The Motley Fool
Analyst Ratings for bluebird bio
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings: 
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Recap: bluebird bio Q3 Earnings
bluebird bio (NASDAQ:BLUE) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Short Volatility Alert: bluebird bio, Inc.
On Wednesday, shares of bluebird bio, Inc. (NASDAQ: BLUE) experienced volatile short activity. After the activity, the stock price went down -10.06% to $6.17. The overall sentiment for BLUE has been... 
Via Benzinga
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
What 5 Analyst Ratings Have To Say About bluebird bio
Analysts have provided the following ratings for bluebird bio (NASDAQ:BLUE) within the last quarter: 
Via Benzinga
Better Buy: CRISPR Therapeutics vs. Bluebird Bio
These two companies have performed almost equally poorly on the stock market in the past year. 
Via The Motley Fool
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via Benzinga
Why Legend Biotech's Shares Jumped 14.2% On Tuesday
The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on. 
Via The Motley Fool
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy
The risk-sharing agreement removes economic uncertainties, enabling regional and mid-sized health plans to provide patients with transfusion-dependent beta-thalassemia access to ZYNTEGLO 
From Real Endpoints
Via GlobeNewswire
Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future
Bluebird Bio Inc (NASDAQ: BLUE) is about to become the seller of the two most expensive drugs in the U.S. and probably the world. The price tag of $3 million is already facing backlash. 
Via Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... 
Via Benzinga
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
US Stock Futures Mixed After Recording Losses Last Week; Fed Speakers In Focus
Pre-open movers 
Via Benzinga
Amazon, bluebird bio And 3 Stocks To Watch Heading Into Monday
With US stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Stitch Fix, Tellurian And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded slightly higher this morning after recording losses in the previous session. Here are some big stocks moving lower in today’s pre-market trading session. 
Via Benzinga
Why ECMOHO Is Trading Lower By 29%; Here Are 28 Stocks Moving Premarket
Gainers Ampio Pharmaceuticals, Inc. (NYSE: AMPE) rose 17.8% to $0.0942 in pre-market trading after declining around 5% on Tuesday. 
Via Benzinga
Why SOBR Safe Shares Surged Around 233%; Here Are 68 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million. 
Via Benzinga
Cognex, Oxford Industries And Some Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping more than 400 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
NIKE Price Target Cut By This Analyst; Also Benchmark Sees $325 For Danaher
Barclays cut the price target on NIKE, Inc. (NYSE: NKE) from $125 to $110. Barclays analyst Adrienne Yih also downgraded the stock from Overweight to Equal-Weight. NIKE shares fell 4.3% to trade at... 
Via Benzinga
Nikola, Super Micro Computer And Other Big Losers From Monday
U.S. stocks closed higher with the Dow Jones gaining around 197 points on Monday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.